Novartis AG Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (50)

Latest Posts

About This Stock More About This Stock
Monday, Monday
Article By: Marvin R Clark
Tuesday, June 13, 2017 1:08 AM EDT
The Dow Industrials fell from record highs, with an inside trading session that does not look like a reversal, not yet anyway. The Nasdaq Composite confirmed its sharp downturn on Friday.
In this article: GE, AAPL, MSFT, FXB, GOOGL, NVS, AMGN
Read
5 Drug Stocks In Focus On World MS Day
Article By: Arpita Dutt
Wednesday, May 31, 2017 11:23 AM EDT
The multiple sclerosis market represents huge commercial potential. Here are some of the key players in the MS market.
In this article: BIIB, TEVA, NVS, SNY, RHHBY
Read
Conatus Pharmaceuticals Launches Small Offering For Pipeline Expansion
Article By: Terry Chrisomalis
Friday, May 12, 2017 7:05 PM EDT
The offering doesn’t seem to make sense after the Novartis (NVS) licensing deal being signed.
In this article: CNAT, NVS, RHHBY
Read
E Conatus Pharmaceuticals Announces Novartis Takes Option To License Emricasan
Article By: Terry Chrisomalis
Saturday, May 6, 2017 11:36 AM EDT
With the option being exercised by Novartis this now opens Conatus to many good perks.
In this article: CNAT, NVS
Read
E Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Article By: Terry Chrisomalis
Sunday, April 30, 2017 11:36 AM EDT
On Friday, Novartis stated that it had won FDA approval for Rydapt, which is a drug developed to treat patients with Acute Myeloid Leukemia -- AML.
In this article: NVS
Read

PARTNER HEADLINES

Latest Tweets for $NVS

No tweets yet!

$NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Terry Chrisomalis 5/1/2017 12:22:24 AM

Yes it does indeed. #Novartis has been doing very well lately. $NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Danielle Rogers 4/30/2017 5:29:49 PM

Triple the effectiveness over a placebo looks very promising! $NVS

1 to 3 of 3 comments